University of Leeds: Multiple Myeloma trials

The registry lists 11 Multiple Myeloma studies with University of Leeds as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 6Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingNCT07649525Phase 3
• The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)RecruitingNCT03562169Phase 3
• Selinexor, Cyclophosphamide and Prednisone in MyelomaCompletedNCT06212596Phase 2
• Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT03720041Phase 3
• Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple MyelomaWithdrawnNCT03191981Phase 1/2
• MUK Nine b: OPTIMUM Treatment ProtocolActive, not recruitingNCT03188172Phase 2
• Viral Immunotherapy in Relapsed/Refractory Multiple MyelomaStatus unknownNCT03015922Phase 1
• Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.CompletedNCT02461888Phase 2
• Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT02406222Phase 2
• Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)CompletedNCT01720875Phase 2
• Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsStatus unknownNCT01554852Phase 3